Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been able to pull that off (and then some) in the past half decade. Naturally, that doesn't automatically make these biotech stocks worth buying. Past performance isn't a guarantee of future success.

Can Regeneron and Moderna deliver similar returns in the next five years? Let's dig in and find out.

Continue reading

Source Fool.com